Info

Response Genetics, Inc. is engaged in the research and development of its clinical diagnostic tests for cancer based on its technologies. The Company generates revenues primarily from sales of its analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. It launched its diagnostic tests under the brand name ResponseDx for non small cell lung cancer and colon cancer. Using its technologies, the Company extracts nucleic acids, such as ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) from tumor specimens that are stored as formalin-fixed and paraffin-embedded (FFPE), specimens and analyze genetic information contained in these tissues. The Company generates clinically relevant information regarding the risks of recurrence of cancer or chemotherapy response using approximately 30,000 genes available from microarray profiling of FFPE specimens.(Source: 10KSB)